Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                FDA User Fee Programs

FDA User Fee Programs

                        OMUFA Reauthorization: Fiscal Years 2026 - 2030
          FDA: User Fees Explained


                        Accredited Third-Party Certification Program User Fees
          Animal Drug User Fee Act (ADUFA)
          Animal Generic Drug User Fee Act (AGDUFA)
          Biosimilar User Fee Amendments
          Color Additive Certification Fees
          Export Certificate Fees
          Freedom of Information Act Fees (FOIA)
          Generic Drug User Fee Amendments
          Human Drug Compounding Outsourcing Facility Fees
          Mammography Facility Fees (MQSA)
          Medical Device User Fee Amendments (MDUFA)
          Over-The-Counter Monograph Drug User Fee Program (OMUFA)
          Prescription Drug User Fee Amendments
          Voluntary Qualified Importer Program User Fees Home
          For Industry
          FDA User Fee Programs
          OMUFA Reauthorization: Fiscal Years 2026 - 2030FDA User Fee Programs OMUFA Reauthorization: Fiscal Years 2026 - 2030
  
  	
    Share
    Post
    Linkedin

    Email
    PrintOn March 27, 2020, “the Coronavirus Aid, Relief, and Economic Security Act” (or the “CARES Act”) (Public Law No. 116-136,) was signed into law. The CARES Act added to the FD&C Act section 505G, which reforms and modernizes the regulation of OTC monograph drugs.  The CARES Act also added to the FD&C Act section 744M, authorizing FDA to assess and collect user fees dedicated to OTC monograph drug activities, and accompanying sections 744L and 744N.

The OTC Monograph Drug User Fee Program, which we refer to as “OMUFA,” is modeled after the successful Prescription Drug User Fee Act (PDUFA). Under the OMUFA program, industry-paid fees help support FDA’s regulatory activities related to OTC monograph drugs and FDA agrees to adhere to performance goals negotiated by FDA and industry, including specific time frames for conducting certain OTC monograph activities. The current legislative authority for OMUFA expires September 30, 2025. At that time, new legislation will be required to reauthorize the OMUFA program for future fiscal years.

FDA has begun the statutorily-directed negotiation process for developing recommendations to reauthorize OMUFA for fiscal years (FYs) 2026 through 2030. Minutes from each FDA meeting with industry will be posted here once they become available.

FDA held a public meeting on OMUFA reauthorization on September 28, 2023, with a docket opened for public comment. Additional details are below. A second public meeting will be announced to the public after negotiation meetings with industry have concluded.

Industry Discussions on Reauthorization

November 28, 2023 (PDF – 177 KB)
	November 14, 2023 (PDF – 128 KB)Public Meetings on Reauthorization

Public Meeting on the Reauthorization of the Over-the-Counter Monograph Drug User Fee Program (OMUFA) - 09/28/2023

                                                                                  Content current as of:
      01/17/2024
              
              
Regulated Product(s)
		 Drugs
			  			     			  						              
			
			
			
			
						  Over-the-Counter DrugsFDA User Fee Programs

          
                        OMUFA Reauthorization: Fiscal Years 2026 - 2030
          FDA: User Fees Explained


                        Accredited Third-Party Certification Program User Fees
          Animal Drug User Fee Act (ADUFA)
          Animal Generic Drug User Fee Act (AGDUFA)
          Biosimilar User Fee Amendments
          Color Additive Certification Fees
          Export Certificate Fees
          Freedom of Information Act Fees (FOIA)
          Generic Drug User Fee Amendments
          Human Drug Compounding Outsourcing Facility Fees
          Mammography Facility Fees (MQSA)
          Medical Device User Fee Amendments (MDUFA)
          Over-The-Counter Monograph Drug User Fee Program (OMUFA)
          Prescription Drug User Fee Amendments
          Voluntary Qualified Importer Program User Fees
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop